PDCD1 and cancer: Given that Science-LUAD cohort was only treated with PD-1 blockade and performed better than Cancer Cell-LUAD cohort on predicting ICB efficacy (Figure 2B; AUC = 0.82 and 0.80, respectively), we stratified the Discovery-LUAD cohort into two groups based on the TMB cutoff from Science-LUAD cohort (Figure 2C; TMB = 166.5).